RxDoctor Payments Data

William Finneran, MD

Cardiovascular Disease · Lancaster, PANPI 1144209586

Payments from drug & device makers

$8,613in general payments, 2019–2025

Across 75 payments — averaging $114.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$4K
  • Pfizer$2K
  • Medtronic$2K
  • Johnson & Johnson$203
  • Boehringer Ingelheim$168
  • Novo Nordisk$125
  • plus $518 from 10 others

What the payments were for

  • Speaking & faculty fees$5,70066%
  • Travel & lodging$87710%
  • Food & beverage$2,03624%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,613 in reported general payments places this provider in the 75th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$154,603
Medicare patients
1,289
Services billed
1,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$151,245
XareltoRivaroxaban26$27,709
Metoprolol Succinate271$3,417
Ezetimibe102$2,638
Amlodipine Besylate366$1,865
Atorvastatin Calcium90$1,297
Rosuvastatin Calcium115$1,211
Isosorbide Mononitrate ErIsosorbide Mononitrate92$1,128
Carvedilol160$969
Losartan Potassium122$900
Nitroglycerin66$833
Lisinopril110$722
Metoprolol Tartrate114$561
Midodrine Hcl12$539
Potassium Chloride25$459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$2,186$151,245167 claims
Johnson & JohnsonXarelto$203$27,70926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →